Welcome to our dedicated page for Royalty Pharma Plc SEC filings (Ticker: RPRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Royalty Pharma plc (Nasdaq: RPRX) files a range of documents with the U.S. Securities and Exchange Commission that provide detailed insight into its royalty-based business model, capital structure and portfolio performance. As a company incorporated in England and Wales with Class A ordinary shares listed on The Nasdaq Stock Market LLC under the symbol RPRX, its SEC filings include annual reports on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K, along with registration statements and indenture-related documents.
In its filings, Royalty Pharma explains how it acquires and manages royalty interests on biopharmaceutical products and defines key metrics such as Portfolio Receipts, royalty receipts, milestones and other contractual receipts. The company also discloses non-GAAP liquidity measures, including Adjusted EBITDA, ROIC Adjusted EBITDA, Portfolio Cash Flow and ROIE Portfolio Cash Flow, and reconciles these to net cash provided by operating activities. Debt-related filings describe senior unsecured notes issued under an indenture among Royalty Pharma plc, Royalty Pharma Holdings Ltd, Royalty Pharma Manager, LLC and Wilmington Trust, National Association, as trustee, including coupon rates, maturities, guarantees and covenant terms.
Form 8-K current reports highlight material events such as quarterly earnings releases, debt offerings, changes in directors and other significant corporate developments. These filings can be used to track Royalty Pharma’s capital deployment into new royalty transactions, updates to its share repurchase program, dividend decisions and other actions affecting shareholders.
On Stock Titan’s SEC filings page for RPRX, users can access Royalty Pharma’s latest 10-K, 10-Q and 8-K filings as they are posted to EDGAR. AI-powered summaries help explain complex sections, such as the description of Portfolio Receipts, non-GAAP liquidity measures, and indenture provisions for senior notes, allowing readers to quickly understand the implications of lengthy documents. The page also surfaces Form 4 insider transaction reports, so users can review trading activity by directors and officers alongside the company’s broader disclosure record.
Royalty Pharma plc (RPRX) – Form 4 insider transaction:
On 31 Jul 2025, director Carole Ho reported receiving 8,558 Class A ordinary shares through two restricted-stock-unit (RSU) grants issued under the 2020 Independent Director Equity Incentive Plan:
- 2,752 RSUs as an initial equity award.
- 5,806 RSUs as a pro-rated annual award.
Both tranches vest 100 % on the earlier of (i) one year from grant or (ii) the next annual shareholders’ meeting. The awards carry a cost basis of $0, reflect routine board compensation, and increase Ho’s direct ownership to 8,558 shares. No shares were sold, no derivatives were involved, and the filing references no Rule 10b5-1 trading plan. The disclosure is informational and does not affect Royalty Pharma’s fundamentals.